Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Evolent Health (EVH) Share Price
Headlines about Evolent Health (NYSE:EVH) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Evolent Health earned a coverage optimism score of 0.14 on Accern’s scale. Accern also assigned headlines about the technology company an impact score of 46.2950887088003 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the headlines that may have effected Accern’s analysis:
- Notable Eye Catching Stocks: First Horizon National Corporation, (NYSE: FHN), Evolent Health, Inc., (NYSE: EVH … – Stocks In The News (press release) (tradingnewsnow.com)
- Evolent Health Inc (EVH) Expected to Post Earnings of -$0.04 Per Share (americanbankingnews.com)
- Premier Health, Virginia company terminate sale of insurance business (finance.yahoo.com)
- Critical Contrast: Press Ganey (PGND) versus Evolent Health (EVH) (americanbankingnews.com)
- Pre-Open Movers 12/08: (STDY) (SIGM) (ALXN) Higher; (AOBC) (TELL) (LJPC) Lower (more…) (streetinsider.com)
Evolent Health (EVH) opened at $13.00 on Wednesday. The company has a current ratio of 3.34, a quick ratio of 3.34 and a debt-to-equity ratio of 0.11. Evolent Health has a 12-month low of $10.30 and a 12-month high of $27.50.
A number of equities analysts recently weighed in on the stock. Robert W. Baird reissued an “outperform” rating and set a $25.00 target price (down previously from $35.00) on shares of Evolent Health in a research note on Tuesday, September 26th. They noted that the move was a valuation call. Cowen reissued an “outperform” rating and set a $29.00 target price (down previously from $33.00) on shares of Evolent Health in a research note on Friday, October 6th. J P Morgan Chase & Co reissued a “buy” rating on shares of Evolent Health in a research note on Friday, August 18th. Leerink Swann set a $32.00 target price on shares of Evolent Health and gave the stock a “buy” rating in a research note on Friday, August 18th. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $30.00 price target on shares of Evolent Health in a report on Sunday, December 3rd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and thirteen have issued a buy rating to the stock. Evolent Health currently has an average rating of “Buy” and a consensus price target of $28.00.
Evolent Health Company Profile
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
Receive News & Stock Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related stocks with our FREE daily email newsletter.